
Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, is now available under national reimbursement in Italy. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for [ Read More ]




